Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Qiang He, Linna Xie, Rongrong Zhao, Ji Ma, Hui Wang, Jie Li, Chuanli Zhao, Y. Lynn Wang, Zengjun Li

Blood (2022) 140 (Supplement 1): 6614–6615.

DOI: https://doi.org/10.1182/blood-2022-168859

Published: 2022

Journal Articles

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Blood (2022) 140 (Supplement 1): 11962–11963.

DOI: https://doi.org/10.1182/blood-2022-162507

Published: 2022

Journal Articles

Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

Hui-qiang Huang, Zengjun Li, Gang Cheng, Gao Yan, Zhihua Yao, Guifang Zhang, Xiaoguang Wang, Zhengxiang Han, Yong Chen, Haijiao Yan, Weie Zheng, Jun Yan, Yulan Gu, Zhangxia Ren, Rusen Zhao, Ningling Zhang, Jun Ma

Blood (2021) 138 (Supplement 1): 4569.

DOI: https://doi.org/10.1182/blood-2021-149884

Published: 2021

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

DOI: https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Blood (2019) 134 (Supplement_1): 4319.

DOI: https://doi.org/10.1182/blood-2019-123331

Published: 2019

Journal Articles

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Blood (2019) 134 (Supplement_1): 4036.

DOI: https://doi.org/10.1182/blood-2019-129305

Published: 2019

Journal Articles

Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China

Weiwei Sui, Gang An, Shuhui Deng, MD, Yan Xu, Mu Hao, Fu Mingwei, Tingyu Wang, Shuhua Yi, MD, Yaozhong Zhao, Dehui Zou, MD, Zengjun Li, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 5581.

DOI: https://doi.org/10.1182/blood-2019-126718

Published: 2019

Journal Articles

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

Shuhua Yi, MD, Yuting Yan, Meiling Jin, Dr., Wenjie Xiong, Zengjun Li, Ying Yu, Rui Cui, MD, Zhen Yu, MD, Yani Lin, Wang Jun, Tingyu Wang, Wei Liu, Kun Ru, MD, Lili Wang, MD PhD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 2761.

DOI: https://doi.org/10.1182/blood-2019-123194

Published: 2019

Journal Articles

Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma

Xuehan Mao, MD, Yan Xu, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Zengjun Li, Lugui Qiu, MD PhD, Gang An

Blood (2019) 134 (Supplement_1): 4363.

DOI: https://doi.org/10.1182/blood-2019-125044

Published: 2019

Journal Articles

Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways

Wenjie Xiong, Shuhua Yi, MD, Yuting Yan, Zengjun Li, Wei Liu, Rui Lv, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 2566.

DOI: https://doi.org/10.1182/blood-2019-129860

Published: 2019

Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD

Blood (2018) 132 (Supplement 1): 5332.

DOI: https://doi.org/10.1182/blood-2018-99-110585

Published: 2018

Journal Articles

The Cytogenetic Aberrations and Their Prognostic Value in 181 Untreated Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia in China

Wenjie Xiong, Yuting Yan, Shuhua Yi, Zengjun Li, Zhen Yu, Wei Liu, Rui Lv, Dehui Zou, Yan Xu, MD, An Gang, MD, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 5160.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.5160.5160

Published: 2017

Journal Articles

Primary Plasma Cell Leukemia in China: A Retrospective Single Center Study

Tengteng Yu, Yan Xu, MD, An Gang, MD, Zengjun Li, Mu Hao, PhD, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 5428.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.5428.5428

Published: 2017

Journal Articles

A Novel Hierarchical Prognostic Model Based on Clinical Feature and Cytogenetics for Splenic Marginal Zone Lymphoma

Yuting Yan, Wenjie Xiong, Shuhua Yi, MD, PhD, Rui Lv, MD, PhD, Zhen Yu, Wei Liu, MD,PhD, Heng Li, Huimin Liu, Zengjun Li, MD, PhD, Dehui Zou, MD, Mu Hao, MD, PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 1808.

DOI: https://doi.org/10.1182/blood.V128.22.1808.1808

Published: 2016

Journal Articles

The Addition of Novel Agents to Front-Line Therapy Significantly Improve the Short-Term and Long-Term Therapeutic Effects of High Risk Waldenstrom's Macroglobulinemia Patients in China

Wenjie Xiong, Shuhua Yi, MD, PhD, Heng Li, Zengjun Li, MD, PhD, Rui Lv, MD, PhD, Wei Liu, MD, PhD, Yan Xu, MD, PhD, Dehui Zou, MD, Mu Hao, MD, PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 5333.

DOI: https://doi.org/10.1182/blood.V128.22.5333.5333

Published: 2016

Journal Articles

The Clinical Features and Prognosis of Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia: A Large Series Analysis from a Single Center

Wenjie Xiong, Shuhua Yi, MD, PhD, Heng Li, Zengjun Li, MD, PhD, Rui Lv, MD, PhD, Wei Liu, MD, PhD, Yan Xu, MD, PhD, Dehui Zou, MD, Mu Hao, MD, PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 5334.

DOI: https://doi.org/10.1182/blood.V128.22.5334.5334

Published: 2016

Journal Articles

Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China

Huimin Liu, Wenjie Xiong, Heng Li, Rui Lv, MD, PhD, Wei Liu, MD, PhD, Shuhua Yi, MD, PhD, Zengjun Li, MD, PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 5336.

DOI: https://doi.org/10.1182/blood.V128.22.5336.5336

Published: 2016

Journal Articles

Development of a Novel Prognostic Scoring System of Time to First Treatment for Chinese Patients with Chronic Lymphocytic Leukemia

Heng Li, Wenjie Xiong, Zengjun Li, MD, PhD, Shuhua Li, MD, PhD, Rui Lv, MD, PhD, Dehui Zou, MD, Lugui Qiu, MD

Blood (2016) 128 (22): 5581.

DOI: https://doi.org/10.1182/blood.V128.22.5581.5581

Published: 2016

Journal Articles

The Investigation of Hepatitis Virus Infection in Different Subtypes of B-Cell Non Hodgkin Lymphoma in China: High Infection of Both HBV and HCV in Splenic Marginal Lymphoma

Wenjie Xiong, Shuhua Yi, MD, PhD, Heng Li, Zengjun Li, MD, PhD, Rui Lv, MD, PhD, Wei Liu, MD, PhD, Yan Xu, MD PhD, Dehui Zou, MD, Lugui Qiu, MD

Blood (2016) 128 (22): 5314.

DOI: https://doi.org/10.1182/blood.V128.22.5314.5314

Published: 2016

Journal Articles

Gene Mutation Signature and Its Pathogenesis Role in Chronic Lymphocytic Leukemia in China: Different from the Western Reports

Shuhua Yi, Sr., Xiong Wenjie, Li Heng, Zhen Yu, Zengjun Li, MD PhD, Yujiao Jia, PhD, Yani Lin, Jun Wang, Gang An, Dehui Zou, MD, Kun Ru, Jianxiang Wang, MD, Tao Cheng, MD, Lugui Qiu, MD

Blood (2016) 128 (22): 4360.

DOI: https://doi.org/10.1182/blood.V128.22.4360.4360

Published: 2016

NARROW

Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma

Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

The Cytogenetic Aberrations and Their Prognostic Value in 181 Untreated Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia in China

Primary Plasma Cell Leukemia in China: A Retrospective Single Center Study

A Novel Hierarchical Prognostic Model Based on Clinical Feature and Cytogenetics for Splenic Marginal Zone Lymphoma

The Addition of Novel Agents to Front-Line Therapy Significantly Improve the Short-Term and Long-Term Therapeutic Effects of High Risk Waldenstrom's Macroglobulinemia Patients in China

The Clinical Features and Prognosis of Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia: A Large Series Analysis from a Single Center

Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China

Development of a Novel Prognostic Scoring System of Time to First Treatment for Chinese Patients with Chronic Lymphocytic Leukemia

The Investigation of Hepatitis Virus Infection in Different Subtypes of B-Cell Non Hodgkin Lymphoma in China: High Infection of Both HBV and HCV in Splenic Marginal Lymphoma

Gene Mutation Signature and Its Pathogenesis Role in Chronic Lymphocytic Leukemia in China: Different from the Western Reports

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only